Abstract: With the increase in the incidence of gastrointestinal neuroendocrine tumors (GEP-NETs), the treatment for gastrointestinal neuroendocrine tumors is gaining more attention. According to the fourth edition of the World Health Organization (WHO) digestive system tumors pathological classification in 2010, the neuroendocrine tumors can be divided into 3 levels: G1, G2, and G3, respectively. Among them, the G1 and G2 level are neuroendocrine tumors, G3 level is neuroendocrine carcinoma. For G1 and G2 level tumors, existing medicine treatments include somatostatin analogs, chemotherapy, targeted therapy, and interferons; while for G3 level neuroendocrine carcinoma, platinum-based chemotherapy is generally prioritized. Recent studies have found that immune factors also contribute to neuroendocrine tumors. Clinical trials on immunotherapy of neuroendocrine tumors are ongoing. In this paper, the drug treatments for GEP-NETs are briefly described.